Lilly signs up for access to Evox’ tech in R&D deal
Evox’ technology modifies exosomes to deliver drugs to areas currently inaccessible
Read More
Tag: RNAi
Mallinckrodt, Silence Theraputics to commercialise RNAi therapeutics
The agreement provides Mallinckrodt with an exclusive worldwide license for C3 (SLN500) – a preclinical asset that targets a specific protein in the complement pathway.
Read More
Sanofi ends option phase of rare disease alliance with Alnylam
Through the agreement Alnylam will advance an additional investigational asset in an undisclosed rare genetic disease.
Read More
Alnylam’s novel RNA therapy Onpattro wins nod for hATTR amyloidosis
The US Food and Drug Administration has approved Alnylam’s RNAi therapeutic Onpattro for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.
Read More
Silence picks up stake in US-based Arrowhead
The UK’s Silence Therapeutics has snapped up a stake in fellow RNA therapeutics group US biotech Arrowhead Pharmaceuticals for around £7.8 million, to expand its potential reach in the field.
Read More
- King’s Doctoral Training Centre to investigate MS symptom management
- Agenda announced for FlyPharma Vienna 2024
- Therapy reprogrammes immune cells to shrink prostate and bladder cancers
- Researchers combine herpes virus with cancer vaccine to treat brain cancer in children
- UK MRC and AstraZeneca partner for translational clinical research
